Oxytocin Antagonist Atosiban for the Treatment of Preterm Labor: Clinical Trial Evidence
Keywords:
Second brain, Gut brainaxis, COVID-19 andmicrobiome, COVID-19 liver effect, Perception; Nursing Student; Induced Abortion., : Pulmonary hydatid cyst (PHC). Video-assisted thoracicsurgery (VATS). Uniportal VATS (U-VATS). Multiportal VATS (M-VATS)., Preterm labor; Oxytocin receptor antagonist; Atosiban; TocolysisAbstract
Objective: This prospective multicentric study was designed to confirm the efficacy and safety of atosiban in preterm labor. Methods: In a study across 14 sites in India, 406 patients with preterm labor symptoms received up to 48 hours of atosiban infusion. Tocolysis efficacy was gauged by the 72-hour undelivered rate, while safety was assessed via maternal-fetal and neonatal adverse events. Results: In 400 evaluated patients, the gestation period in 89% of patients was prolonged for more than 48 hours and 83.75% of patients continued their pregnancy up to 72 hours. Amongst the tocolyzed patients, 77% of preterm births were prevented for more than 7 days. The mean duration of gestational period prolongation after the tocolysis was 31.28 days with a mean gestational age at delivery of 35.0 ± 3.15 weeks. Singleton and twin pregnancy prolongation rates for 72 hours were 84.95% and 67.86% respectively. Birth weight of more than 2500 grams was in 54.44% of neonates and an APGAR score of more than 7 after 5 minutes was in 91.82% of neonates. Patients receiving atosiban were more likely to have nausea (2.71%), tachycardia (2.46%), and headache (1.97%). No new or unexpected adverse events were reported in this study.References
Chawan Paiboon, J P Vogel, A B Moller, et al (2019) Global, regional, and national estimates of levels of preterm birth in 2014: A systematic review and modelling analysis. 7(1), e37–e46. https://doi.org/10.1016/S2214-109X(18)30451-0
H Blencowe, S Cousens, F B Jassir, et al, Lancet Stillbirth Epidemiology Investigator Group (2016) National, regional, and worldwide estimates of stillbirth rates in 2015, with trends from 2000: a systematic analysis. 4(2), e98-e108. https://doi.org/10.1016/S2214-109X(15)00275-2
A Humberg, I Fortmann, B Siller, et al (2020) Preterm birth and sustained inflammation: consequences for the neonate. 42(4), 451-468. https://doi.org/10.1007/s00281-020-00803-2
L Liu, S Oza, D Hogan, et al (2016) Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals. 388(10063), 3027-3035. https://doi.org/10.1016/S0140-6736(16)31593-8
I Ingemarsson, R F Lamont (2003) An update on the controversies of tocolytic therapy for the prevention of preterm birth. 82(1), 1-9. https://doi.org/10.1034/j.1600-0412.2003.820101.x
World Health Organization (2022) WHO recommendation on tocolytic therapy for improving preterm birth outcomes. https://www.who.int/publications/i/item/9789240057227
A R Fuchs, F Fuchs, P Husslein, et al (1982) Oxytocin receptors and human parturition: a dual role for oxytocin in the initiation of labor. 215(4538), 1396-8. https://doi.org/10.1126/science.6278592
N Vrachnis, F M Malamas, S Sifakis, et al (2011) The oxytocin-oxytocin receptor system and its antagonists as tocolytic agents. 350546. https://doi.org/10.1155/2011/350546
T M Goodwin, A Zograbyan (1998) Oxytocin receptor antagonists. Update. 859-71.
V Suman, E E Luther (2022) Preterm Labor. https://www.ncbi.nlm.nih.gov/books/NBK536939/
J Y Shim, Y W Park, B H Yoon, et al (2006) Multicentre, parallel group, randomised, single-blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women. 113(11), 1228-34. https://doi.org/10.1111/j.1471-0528.2006.01053.x
R F Lamont, K R Kam (2008) Atosiban as a tocolytic for the treatment of spontaneous preterm labor. 3(2), 163-74. https://doi.org/10.1586/17474108.3.2.163
C D Lamont, J S Jørgensen, R F Lamont (2016) The safety of tocolytics used for the inhibition of preterm labour. 15(9), 1163-73. https://doi.org/10.1080/14740338.2016
R Salim, G Garmi, Z Nachum, N Zafran, S Baram, E Shalev (2012) Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. 120(6), 1323-31. https://doi.org/10.1097/aog.ob013e3182755dff
J M Moutquin, D Sherman, H Cohen, et al (2000) Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. 182(5), 1191-9. https://doi.org/10.1067/mob.2000.104950
J Perin, A Mulick, D Yeung, et al (2022) Global, regional, and national causes of under-5 mortality in 2000-19: an updated systematic analysis with implications for the Sustainable Development Goals. 6(2), 106-115. https://doi.org/10.1016/S2352-4642(21)00311-4
T M S Van Winden, T A J Nijman, C E Kleinrouweler, et al (2022) Tocolysis with nifedipine versus atosiban and perinatal outcome: an individual participant data meta-analysis. 22(1), 567. https://doi.org/10.1186/s12884-022-04854-1
S Shaikh, R Mayekar, A Bhosale, et al (2016) Atosiban– Its Impact on Uterine Activity in Preterm Labour. 18(2), 1-8. https://doi.org/10.9734/BJMMR/2016/28846
R K Bhatt, A Kapur, S Choudhary, et al (2021) Initial experience with the oxytocin antagonist atosiban for preterm labor in a tertiary care centre: prospective observational cohort study. 470-76.
D Kiatsuda, J Thinkhamrop, W Prasert charoensuk (2016) Success rate in preterm uterine contraction inhibition with tocolytic agents in a tertiary care center. (8), 663-667. https://doi.org/10.2147/IJWH.S122781
Yu Yang, Yang, Wu, et al. (2020) Effectiveness and safety of atosiban versus conventional treatment in the management of preterm labor. 59(5), 682-685. https://doi.org/10.1016/j.tjog.2020.07.010
R Romero, B M Sibai, L Sanchez-Ramos, et al. (2000) An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. 182(5), 1173-83. https://doi.org/10.1067/mob.2000.95834
R De Heus, B W Mol, J H M Erwich, et al. (2009) Adverse drug reactions to tocolytic treatment for preterm labour: prospective cohort study. b744. https://doi.org/10.1136/bmj.b744
W R Al-Omari, H B Al-Shammaa, E M Al-Tikriti, et al. (2006) Atosiban and nifedipine in acute tocolysis: a comparative study. 128(1-2), 129-34. https://doi.org/10.1016/j.ejogrb.2005.12.010
A A Ali, A K Sayed, L A El Sherif, et al. (2019) Systematic review and meta-analysis of randomized controlled trials of atosiban versus nifedipine for inhibition of preterm labor. 145(2), 139-48. https://doi.org/10.1002/ijgo.12793
Helmer Brunbauer, M Rohrmeister (2003) Exploring the role of tractocile in everyday clinical practice. 110(20), 113-15. https://doi.org/10.1016/s1470-0328(03)00056-9
Husslein (2002) Development and clinical experience with the new evidence-based tocolytic atosiban. 81(7), 633-41. https://doi.org/10.1034/j.1600-0412.2002.810709.x
Marilena Mariavittoria, Giovanni N, Marilena M, et al. (2016) Two cycles of atosiban in preventing preterm birth in twin pregnancies. 2(4), 221-224. https://doi.org/10.15761/COGRM.1000155
O N Richter, C Dorn, P van de Vondel, et al. (2005) Tocolysis with atosiban: experience in the management of premature labor before 24 weeks of pregnancy. 272(1), 26-30. https://doi.org/10.1007/s00404-004-0652-8
M Khalil, R Saad, A Ibrahim (2019) Initial cervical dilation and the association of the success of atosiban. 5(2), 103-106. https://doi.org/10.15406/ipcb.2019.05.00156
S Lurie, O Sadan, Z Ben Aroya (2004) Atosiban treatment for uterine hyperactivity during active labor: a pilot study. 32(2), 137-9. https://doi.org/10.1515/JPM.2004.025
B Dewan, D Shah (2016) The clinical experience of atosiban in preterm labour. 13(7), 1–9. https://doi.org/10.9734/bjmmr/2016/23823
M Shendy, H Hendawy, A Salem (2021) Preterm Labour. https://doi.org/10.5772/intechopen.96049
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Authors and Global Journals Private Limited
This work is licensed under a Creative Commons Attribution 4.0 International License.
